TORONTO, Nov. 18, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO)
("Biosign" or the "Company") is pleased to announce the execution of a
license agreement with Saint John NB based applepeak software to
acquire a fully paid up, perpetual, royalty free, non-exclusive license
to use and modify the source code for the "applepeak Wellness Record" software platform.
On April 26, 2012 applepeak's Wellness Record received a Silver Edison Award in the Lifestyle & Social Impact category. Being recognized with an
Edison Award has become one of the highest accolades a company can
receive in the name of innovation and business. The awards are named
after Thomas Alva Edison (1847-1931) whose inventions, new product
development methods and innovative achievements literally changed the
world, garnered him 1,093 U.S. patents, and made him a household name.
The Wellness Record enables organizations to improve the outcomes of
their health and wellness initiatives and yield positive returns
through a combination of evidence based e-health content, online health
risk assessments, informational resources, flexible e-learning
technologies, health management tools, and professional
oversight/support services. It's an innovative platform that gives
individuals private, personalized online wellness resources to manage
their health including interactive health tools, certified medical
content, fitness and medical device integration, health trackers,
goal-setting tools, clinical monitoring, and program-based social
media.
Biosign will now integrate features from the Wellness Record into our
next iteration of Healthanywhere™. The total license fee of $175,000 was satisfied with the issuance of
3.5 million common shares of Biosign at $0.05/share. The transaction is
subject to board & TSX approval, and all securities issued are subject
to a hold period of 4 months and 1 day, plus further agreed-upon
restrictions on selling over a period of 24 months.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software
enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring /
self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for
cardiovascular clinical decision support and self-care, while its
Healthanywhere™ solution offers industry-leading remote patient
monitoring and patient centred care management. The Company also offers
a number of cardiovascular screening programs for consumers under its
Heart Friendly™ brand, including Heart Friendly™ Practice, Heart
Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on
Biosign, please visit www.biosign.com
About the Edison Awards
The Palos Park, IL based Edison Awards represent the spirit of
innovation personified by Thomas Edison, inspiring the drive of global
inventors to remain in the forefront of creativity and ingenuity.
Sponsors of the 2012 Edison Awards included Nielsen, USA TODAY,
Discovery Communications, SCIENCE, CSRware, and ViridiSTOR. For more
information go to www.edisonawards.com
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in the company's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
